Publication: 2019 thai guidelines on the treatment of hypertension: Executive summary
Submitted Date
Received Date
Accepted Date
Issued Date
2021-10-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
01252208
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-85117217350
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.104, No.10 (2021)
Citation
Sirisawat Kunanon, Pairoj Chattranukulchai, Chavalit Chotruangnapa, Weerapat Kositanurit, Komsing Methavigul, Thananya Boonyasirinant, Petch Rawdaree, Sirakarn Tejavanija, Tuangsit Wataganara, Bancha Satirapoj, Weranuj Roubsanthisuk, Nijasri C. Suwanwela, Somkiat Sangwatanaroj, Rapeephon Kunjara Na Ayudhya, Surapun Sitthisook, Apichard Sukonthasarn (2021). 2019 thai guidelines on the treatment of hypertension: Executive summary. Retrieved from: https://hdl.handle.net/20.500.14594/77801.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
2019 thai guidelines on the treatment of hypertension: Executive summary
Alternative Title(s)
Author(s)
Sirisawat Kunanon
Pairoj Chattranukulchai
Chavalit Chotruangnapa
Weerapat Kositanurit
Komsing Methavigul
Thananya Boonyasirinant
Petch Rawdaree
Sirakarn Tejavanija
Tuangsit Wataganara
Bancha Satirapoj
Weranuj Roubsanthisuk
Nijasri C. Suwanwela
Somkiat Sangwatanaroj
Rapeephon Kunjara Na Ayudhya
Surapun Sitthisook
Apichard Sukonthasarn
Pairoj Chattranukulchai
Chavalit Chotruangnapa
Weerapat Kositanurit
Komsing Methavigul
Thananya Boonyasirinant
Petch Rawdaree
Sirakarn Tejavanija
Tuangsit Wataganara
Bancha Satirapoj
Weranuj Roubsanthisuk
Nijasri C. Suwanwela
Somkiat Sangwatanaroj
Rapeephon Kunjara Na Ayudhya
Surapun Sitthisook
Apichard Sukonthasarn
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Series
Has Part
Abstract
The revision committee of the 2019 Thai Guidelines on the Treatment of Hypertension has reviewed new developments in the body of knowledge, together with the expertise in real-life clinical practice and evidence collected from clinical studies worldwide. The guidelines consist of newly highlighted key topics to ensure the guidelines remain up to date, user friendly, and suitable for the country's context. The guidelines still maintain the current office blood pressure (BP) cut-off point of 140/90 mmHg for the diagnosis of hypertension. The use of out-of-office BP measurements, including home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM), is also advocated to confirm the diagnosis of hypertension. Target BP levels depend on the age of the patients, such as 120 to 130/70 to 79 mmHg for patients aged 18 to 65 years old, or 130 to 139/70 to 79 mmHg for patients over 65 years of age. There are five main groups of antihypertensive medication, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium-channel blockers, and thiazides or thiazide-like diuretics. Two types of medications should be started for most patients, except for frail elderly patients, patients with a relatively low initial BP of 140 to 149/90 to 99 mmHg, and low-risk patients, in which only one type of starting medication should be selected. Medication that involves a combination of two types in one pill should ideally be selected.